Discussion

Cardiovascular disease remains the main cause of morbidity and mortality in the developed world. Fibrin clot structure and fibrinolysis can determine predisposition to CVD and manipulating the prothrombotic environment can reduce the risk of vascular events. Current treatment strategies are only partially effective at reducing the thrombotic milieu, and frequently associated with adverse events secondary to bleeding. Identification of new therapeutic targets is necessary to reduce thrombosis potential in high risk subjects.